{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:25:56Z","timestamp":1792661156120,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.transci.2025.104209","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:23:39Z","timestamp":1752794619000},"page":"104209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lipoprotein apheresis: Current overview and future outlook in clinical practice"],"prefix":"10.1016","volume":"64","author":[{"given":"V.J.J.","family":"Schettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"148","key":"10.1016\/j.transci.2025.104209_bib1","first-page":"e44","article-title":"State of the art: lipoprotein apheresis","volume":"8","author":"Schatz","year":"2023","journal-title":"Dtsch Med Woche"},{"issue":"44","key":"10.1016\/j.transci.2025.104209_bib2","first-page":"e304","article-title":"Lipoprotein apheresis: utility, outcomes, and implementation in clinical practice: a scientific statement from the american heart association","volume":"12","author":"Gianos","year":"2024","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"404","key":"10.1016\/j.transci.2025.104209_bib3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(24)01308-4","article-title":"Lipoprotein(a) and cardiovascular disease","volume":"10459","author":"Nordestgaard","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2025.104209_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2017.05.034","article-title":"History of lipidology and lipoprotein apheresis","volume":"30","author":"Julius","year":"2017","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.transci.2025.104209_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.atherosclerosissup.2015.02.002","article-title":"Managing homozygous familial hypercholesterolaemia from cradle to grave","volume":"18","author":"Thompson","year":"2015","journal-title":"Atheroscler Suppl"},{"key":"10.1016\/j.transci.2025.104209_bib6","unstructured":"Gassen A., Steiner S., Hofmeister S.German National Association of Statutory Health Insurance Physicians. Quality Report 2024 - Reporting Year 2023 Im Internet: \u3008https:\/\/www.kbv.de\/media\/sp\/KBV-Qualitaetsbericht_2024.pdf\u3009."},{"issue":"62","key":"10.1016\/j.transci.2025.104209_bib7","article-title":"The world apheresis association registry, 2023 update","volume":"6","author":"Vrielink","year":"2023","journal-title":"Transfus Apher Sci"},{"issue":"15","key":"10.1016\/j.transci.2025.104209_bib8","first-page":"42","article-title":"The 1(st) and the 2(nd) Italian Consensus Conferences on low-density lipoprotein-apheresis. A practical synopsis and update","volume":"1","author":"Stefanutti","year":"2017","journal-title":"Blood Transfus"},{"issue":"57","key":"10.1016\/j.transci.2025.104209_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.transci.2018.07.015","article-title":"Reduced incidence of cardiovascular events in hyper-Lp(a) patients on lipoprotein apheresis. The G.I.L.A. (Gruppo Interdisciplinare Aferesi Lipoproteica) pilot study","volume":"5","author":"Bigazzi","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"25","key":"10.1016\/j.transci.2025.104209_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11883-023-01113-2","article-title":"Lipoprotein apheresis: current recommendations for treating familial hypercholesterolemia and elevated lipoprotein(a)","volume":"7","author":"Safarova","year":"2023","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2025.104209_bib11","unstructured":"V. Schettler, W. Bernhardt, K. de Groot, C. Fassbender, P. Gr\u00fctzmacher, F. Heigl et al. Standard of Therapeutic Apheresis 2023 - Update 2025 by the German Society for Nephrology (11.04.2025). Im Internet: \u3008https:\/\/www.dgfn.eu\/apherese-standard.html\u3009; 2025."},{"key":"10.1016\/j.transci.2025.104209_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2024.118601","article-title":"The German lipoprotein apheresis registry-summary of the eleventh annual report","volume":"398","author":"Schettler","year":"2024","journal-title":"Atherosclerosis"},{"issue":"41","key":"10.1016\/j.transci.2025.104209_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"1","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.transci.2025.104209_bib14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2352-4642(24)00073-7","article-title":"Cardiovascular outcomes in patients with homozygous familial hypercholesterolaemia on lipoprotein apheresis initiated during childhood: long-term follow-up of an international cohort from two registries","volume":"7","author":"Reijman","year":"2024","journal-title":"Lancet Child Adolesc Health"},{"issue":"399","key":"10.1016\/j.transci.2025.104209_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"10326","author":"Tromp","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.transci.2025.104209_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacl.2025.05.003","article-title":"Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia - a physician survey","author":"Schonck","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"31","key":"10.1016\/j.transci.2025.104209_bib17","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/eurjpc\/zwae036","article-title":"Contemporary lipid-lowering management and risk of cardiovascular events in homozygous familial hypercholesterolaemia: insights from the Italian LIPIGEN Registry","volume":"8","author":"D'Erasmo","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"31","key":"10.1016\/j.transci.2025.104209_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurjpc\/zwae199","article-title":"Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study","volume":"15","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"374","key":"10.1016\/j.transci.2025.104209_bib19","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"7","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"issue":"117","key":"10.1016\/j.transci.2025.104209_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"2","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"43","key":"10.1016\/j.transci.2025.104209_bib21","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"39","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.transci.2025.104209_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120420","article-title":"Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials","volume":"408","author":"Xie","year":"2025","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.transci.2025.104209_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of Bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"3","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"388","key":"10.1016\/j.transci.2025.104209_bib24","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"15","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2025.104209_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pcad.2023.02.007","article-title":"PCSK9 inhibitor, ezetimibe, and bempedoic acid: evidence-based therapies for statin-intolerant patients","volume":"79","author":"Gunta","year":"2023","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.transci.2025.104209_bib26","first-page":"410","article-title":"Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia","author":"Stirnkorb","year":"2025","journal-title":"J Pediatr Endocrinol Metab 4 (38"},{"issue":"18","key":"10.1016\/j.transci.2025.104209_bib27","doi-asserted-by":"crossref","first-page":"e817","DOI":"10.1016\/j.jacl.2024.05.006","article-title":"Real-world experience of long-term efficacy and safety of evinacumab in patients with homozygous familial hypercholesterolemia treated and untreated with lipoprotein apheresis","volume":"5","author":"Stefanutti","year":"2024","journal-title":"J Clin Lipido"},{"key":"10.1016\/j.transci.2025.104209_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.119234","article-title":"Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C","volume":"406","author":"Nigmann","year":"2025","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.transci.2025.104209_bib29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1744-9987.13856","article-title":"Complementary role of evinacumab in combination with lipoprotein apheresis in patients with homozygous familial hypercholesterolemia","volume":"26","author":"Duell","year":"2022","journal-title":"Ther Apher Dial"},{"issue":"51","key":"10.1016\/j.transci.2025.104209_bib30","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1007\/s11033-024-10003-y","article-title":"Lomitapide: navigating cardiovascular challenges with innovative therapies","volume":"1","author":"Munkhsaikhan","year":"2024","journal-title":"Mol Biol Rep"},{"issue":"27","key":"10.1016\/j.transci.2025.104209_bib31","first-page":"22","article-title":"Homozygous familial hypercholesterolemia treatment: new developments","volume":"1","author":"Blom","year":"2025","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.transci.2025.104209_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"333","key":"10.1016\/j.transci.2025.104209_bib33","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Oral muvalaplin for lowering of lipoprotein(a): a randomized clinical trial","volume":"3","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.transci.2025.104209_bib34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front Cardiovasc Med"},{"issue":"148","key":"10.1016\/j.transci.2025.104209_bib35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1161\/CIRCULATIONAHA.123.066510","article-title":"The time to initiate anti-inflammatory therapy for patients with chronic coronary atherosclerosis has arrived","volume":"14","author":"Ridker","year":"2023","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.transci.2025.104209_bib36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.atherosclerosissup.2012.10.017","article-title":"Lipoprotein apheresis--more than just cholesterol reduction?","volume":"1","author":"Neumann","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"37","key":"10.1016\/j.transci.2025.104209_bib37","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehw388","article-title":"Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial","volume":"48","author":"Moriarty","year":"2016","journal-title":"Eur Heart J"},{"issue":"24","key":"10.1016\/j.transci.2025.104209_bib38","first-page":"163","article-title":"Lipoproteinapheresis [Lipoproteinapherese","volume":"4","author":"Schettler","year":"2020","journal-title":"Dial Aktuel"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050225001478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T15:17:10Z","timestamp":1757517430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050225001478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1473050225001478"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2025.104209","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein apheresis: Current overview and future outlook in clinical practice","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2025.104209","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104209"}}